research use only
Cat.No.S9693
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other Guanylate Cyclase Inhibitors | ODQ BAY 41-2272 |
|
In vitro |
DMSO
: 85 mg/mL
(199.35 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 426.38 | Formula | C19H16F2N8O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1350653-20-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | BAY1021189 | Smiles | COC(=O)NC1=C(N)N=C(N=C1N)C2=N[N](CC3=CC=CC=C3F)C4=NC=C(F)C=C24 | ||
| Targets/IC50/Ki |
sGC
|
|---|---|
| In vitro |
The stimulation of sGC by Vericiguat is examined with a recombinant CHO cell line overexpressing rat sGC. This compound stimulates the sGC reporter cell line concentration dependently with an EC50 of 1005 ± 145 nM. In the presence of the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) (30 and 100 nM), the EC50 value shifts to 39.0 ± 5.1 and 10.6 ± 1.7 nM, respectively. In the presence of ODQ, pretreatment of the sGC reporter cell line with 10 μM ODQ for 3 h results in a significantly reduced efficacy of this chemical, with an EC50 of 256 ± 40 nM being observed. |
| In vivo |
This compound can maintain heart and kidney function in a model of hypertension-induced end-organ damage with substantially reduced overall mortality. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06363110 | Active not recruiting | Chronic Heart Failure With Reduced Ejection Fraction |
Bayer |
April 10 2024 | -- |
| NCT06148935 | Recruiting | Chronic Heart Failure With Reduced Ejection Fraction |
Bayer |
November 30 2023 | -- |
| NCT05974189 | Active not recruiting | Chronic Heart Failure With Reduced Ejection Fraction |
Bayer |
July 11 2023 | -- |
| NCT05711719 | Recruiting | Metabolic Syndrome|Coronary Microvascular Dysfunction |
Johns Hopkins University|Merck Sharp & Dohme LLC |
June 16 2023 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.